- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$742.35 | -0.3% | 17.9% | US$653.5b | US$977.47 | PE79.9x | E24.8% | 0.8% | ||
RGEN | US$167.92 | 7.3% | -10.2% | US$9.0b | US$191.46 | PS14.9x | E42.2% | n/a | ||
VRTX | US$427.89 | 3.9% | -2.7% | US$108.7b | US$489.81 | PS10.4x | E36.7% | n/a | ||
BLFS | US$27.48 | 4.6% | 57.6% | US$1.2b | US$31.00 | PS8.7x | E63.4% | n/a | ||
VCYT | US$43.60 | 6.2% | 64.7% | US$3.1b | US$43.22 | PS7.9x | E46.2% | n/a | ||
CDXC | US$6.09 | 12.1% | 347.8% | US$454.7m | US$7.96 | PE313.9x | E81.8% | n/a | ||
MLAB | US$146.64 | 11.9% | 57.7% | US$758.3m | US$133.33 | PS3.5x | E124.7% | 0.4% |
Page 1 of 1